In addition, we used a BT474-HR clone which we selected for its resistance to the effects of the ErbB-2 antibody trastuzumab, employed for treatment of ErbB-2-positive breast cancer (Additional file1: Figure 4A) and the BT474-HR6 clone selected for its resistance to trastuzumab in a previous work[27]. Here, ERBB2 is linked to breast carcinoma.